Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 735

1.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines.

Tieu J, Smith R, Basu N, Brogan P, D'Cruz D, Dhaun N, Flossmann O, Harper L, Jones RB, Lanyon PC, Luqmani RA, McAdoo SP, Mukhtyar C, Pearce FA, Pusey CD, Robson JC, Salama AD, Smyth L, Watts RA, Willcocks LC, Jayne DRW.

Rheumatology (Oxford). 2020 Feb 24. pii: kez640. doi: 10.1093/rheumatology/kez640. [Epub ahead of print] No abstract available.

PMID:
32096545
2.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary.

Tieu J, Smith R, Basu N, Brogan P, D'Cruz D, Dhaun N, Flossmann O, Harper L, Jones RB, Lanyon PC, Luqmani RA, McAdoo SP, Mukhtyar C, Pearce FA, Pusey CD, Robson JC, Salama AD, Smyth L, Watts RA, Willcocks LC, Jayne DRW.

Rheumatology (Oxford). 2020 Feb 24. pii: kez632. doi: 10.1093/rheumatology/kez632. [Epub ahead of print] No abstract available.

PMID:
32096542
3.

Integrated assessment of viral transcription, antigen presentation, and CD8+ T cell function reveal multiple limitations of class I selective HDACi during HIV-1 latency reversal.

Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, Leyre L, Bui TD, Rohwetter TM, Kovacs CM, Benko E, MacLaren L, Wimpelberg A, Cannon CC, Hardy WD, Safrit JT, Jones RB.

J Virol. 2020 Feb 12. pii: JVI.01845-19. doi: 10.1128/JVI.01845-19. [Epub ahead of print]

PMID:
32051267
4.

Human milk oligosaccharide 2'-fucosyllactose links feedings at 1 month to cognitive development at 24 months in infants of normal and overweight mothers.

Berger PK, Plows JF, Jones RB, Alderete TL, Yonemitsu C, Poulsen M, Ryoo JH, Peterson BS, Bode L, Goran MI.

PLoS One. 2020 Feb 12;15(2):e0228323. doi: 10.1371/journal.pone.0228323. eCollection 2020.

5.

BCL-2 antagonism sensitizes cytotoxic t cell-resistant hiv reservoirs to elimination ex vivo.

Ren Y, Huang SH, Patel S, Conce Alberto WD, Magat D, Ahimovic DJ, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon CM, Hardy WD, Bosque A, Bollard CM, Jones RB.

J Clin Invest. 2020 Feb 6. pii: 132374. doi: 10.1172/JCI132374. [Epub ahead of print]

6.

Differences in inducibility of the latent HIV reservoir in perinatal and adult infection.

Dhummakupt A, Rubens JH, Anderson T, Powell L, Nonyane BA, Siems LV, Collinson-Streng A, Nilles T, Jones RB, Tepper V, Agwu A, Persaud D.

JCI Insight. 2020 Feb 27;5(4). pii: 134105. doi: 10.1172/jci.insight.134105.

7.

Inhibition of HIV Replication by Apolipoprotein A-I Binding Protein Targeting the Lipid Rafts.

Dubrovsky L, Ward A, Choi SH, Pushkarsky T, Brichacek B, Vanpouille C, Adzhubei AA, Mukhamedova N, Sviridov D, Margolis L, Jones RB, Miller YI, Bukrinsky M.

mBio. 2020 Jan 21;11(1). pii: e02956-19. doi: 10.1128/mBio.02956-19.

8.

HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform.

Patel S, Hanajiri R, Grant M, Saunders D, Van Pelt S, Keller M, Hanley PJ, Simon G, Nixon DF, Hardy D, Jones RB, Bollard CM.

Mol Ther Methods Clin Dev. 2019 Oct 11;16:11-20. doi: 10.1016/j.omtm.2019.10.001. eCollection 2020 Mar 13.

9.

T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.

Macatangay BJC, Gandhi RT, Jones RB, Mcmahon DK, Lalama CM, Bosch RJ, Cyktor JC, Thomas AS, Borowski L, Riddler SA, Hogg E, Stevenson E, Eron JJ, Mellors JW, Rinaldo CR; ACTG A5321 Team.

AIDS. 2020 Jan 1;34(1):15-24. doi: 10.1097/QAD.0000000000002406.

PMID:
31634201
10.

HTLV-1 as a Model for Virus and Host Coordinated Immunoediting.

Mota TM, Jones RB.

Front Immunol. 2019 Sep 24;10:2259. doi: 10.3389/fimmu.2019.02259. eCollection 2019.

11.

Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.

Dorsett KA, Jones RB, Ankenbauer KE, Hjelmeland AB, Bellis SL.

J Ovarian Res. 2019 Oct 14;12(1):93. doi: 10.1186/s13048-019-0574-5.

12.

Transcriptomic analysis of human endogenous retroviruses in systemic lupus erythematosus.

Iñiguez LP, de Mulder Rougvie M, Stearrett N, Jones RB, Ormsby CE, Reyes-Terán G, Crandall KA, Nixon DF, Bendall ML.

Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21350-21351. doi: 10.1073/pnas.1907705116. Epub 2019 Oct 8. No abstract available.

13.

Telescope: Characterization of the retrotranscriptome by accurate estimation of transposable element expression.

Bendall ML, de Mulder M, Iñiguez LP, Lecanda-Sánchez A, Pérez-Losada M, Ostrowski MA, Jones RB, Mulder LCF, Reyes-Terán G, Crandall KA, Ormsby CE, Nixon DF.

PLoS Comput Biol. 2019 Sep 30;15(9):e1006453. doi: 10.1371/journal.pcbi.1006453. eCollection 2019 Sep.

14.
15.

Have Cells Harboring the HIV Reservoir Been Immunoedited?

Huang SH, McCann CD, Mota TM, Wang C, Lipkin SM, Jones RB.

Front Immunol. 2019 Aug 6;10:1842. doi: 10.3389/fimmu.2019.01842. eCollection 2019.

16.

Maternal blood pressure mediates the association between maternal obesity and infant weight gain in early postpartum.

Berger PK, Plows JF, Jones RB, Pollock NK, Alderete TL, Ryoo JH, Goran MI.

Pediatr Obes. 2019 Nov;14(11):e12560. doi: 10.1111/ijpo.12560. Epub 2019 Jul 11.

PMID:
31297972
17.

Treatment of Relapses in ANCA-Associated Vasculitis.

McClure M, Jones RB.

Clin J Am Soc Nephrol. 2019 Jul 5;14(7):967-969. doi: 10.2215/CJN.06250519. Epub 2019 Jun 28. No abstract available.

PMID:
31278112
18.

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.

Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D.

RMD Open. 2019 Jun 5;5(1):e000905. doi: 10.1136/rmdopen-2019-000905. eCollection 2019.

19.

Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.

Barrett C, Willcocks LC, Jones RB, Tarzi RM, Henderson RB, Cai G, Gisbert SI, Belson AS, Savage CO.

Nephrol Dial Transplant. 2019 Jun 26. pii: gfz086. doi: 10.1093/ndt/gfz086. [Epub ahead of print]

PMID:
31243451
20.

Response to: 'Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones et al' by Vandergheynst et al.

Jones RB, Hiemstra TF, Walsh M, Jayne D, Harper L.

Ann Rheum Dis. 2019 Jun 19. pii: annrheumdis-2019-215658. doi: 10.1136/annrheumdis-2019-215658. [Epub ahead of print] No abstract available.

PMID:
31217171
21.

Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients.

Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, Emmi G, Moroni G, Sinico RA, Messa P, Hall F, Vaglio A, Gallieni M, Jayne DR.

Arthritis Rheumatol. 2019 Oct;71(10):1670-1680. doi: 10.1002/art.40932. Epub 2019 Aug 30.

22.

Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.

Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT; ACTG 5321 Team.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):594-599. doi: 10.1097/QAI.0000000000002080.

PMID:
31045647
23.

High intake of dietary fructose in overweight/obese teenagers associated with depletion of Eubacterium and Streptococcus in gut microbiome.

Jones RB, Alderete TL, Kim JS, Millstein J, Gilliland FD, Goran MI.

Gut Microbes. 2019;10(6):712-719. doi: 10.1080/19490976.2019.1592420. Epub 2019 Apr 16.

PMID:
30991877
24.

HIV Controllers Exhibit Effective CD8+ T Cell Recognition of HIV-1-Infected Non-activated CD4+ T Cells.

Monel B, McKeon A, Lamothe-Molina P, Jani P, Boucau J, Pacheco Y, Jones RB, Le Gall S, Walker BD.

Cell Rep. 2019 Apr 2;27(1):142-153.e4. doi: 10.1016/j.celrep.2019.03.016.

25.

Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.

Takata H, Kessing C, Sy A, Lima N, Sciumbata J, Mori L, Jones RB, Chomont N, Michael NL, Valente S, Trautmann L.

J Virol. 2019 May 15;93(11). pii: e02248-18. doi: 10.1128/JVI.02248-18. Print 2019 Jun 1.

26.

Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.

McClure ME, Wason J, Gopaluni S, Tieu J, Smith RM, Jayne DR, Jones RB.

J Clin Rheumatol. 2019 Aug;25(5):217-223. doi: 10.1097/RHU.0000000000001030.

PMID:
30896460
27.

Response to: 'MYCYC, unravelling the long road ahead in ANCA-associated vasculitis' by Jain et al.

Harper L, Jones RB.

Ann Rheum Dis. 2019 Mar 20. pii: annrheumdis-2019-215254. doi: 10.1136/annrheumdis-2019-215254. [Epub ahead of print] No abstract available.

PMID:
30894344
29.

Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion.

Pinzone MR, VanBelzen DJ, Weissman S, Bertuccio MP, Cannon L, Venanzi-Rullo E, Migueles S, Jones RB, Mota T, Joseph SB, Groen K, Pasternak AO, Hwang WT, Sherman B, Vourekas A, Nunnari G, O'Doherty U.

Nat Commun. 2019 Feb 13;10(1):728. doi: 10.1038/s41467-019-08431-7.

30.

Current challenges and recent advances in the search for a cure for HIV.

Jones RB.

J Int AIDS Soc. 2019 Feb;22(2):e25248. doi: 10.1002/jia2.25248. No abstract available.

31.

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J, Hamour S, Burns A, Griffith M, Galliford J, Levy JB, Cairns TD, Gopaluni S, Jones RB, Jayne D, Little MA, Pusey CD, Salama AD.

Rheumatology (Oxford). 2019 Feb 1;58(2):373. doi: 10.1093/rheumatology/kez001. No abstract available.

PMID:
30690635
32.

Effect of Tuberosity Healing on Clinical Outcomes in Elderly Patients Treated With a Reverse Shoulder Arthroplasty for 3- and 4-Part Proximal Humerus Fractures.

Simovitch RW, Roche CP, Jones RB, Routman HD, Marczuk Y, Wright TW, Zuckerman JD.

J Orthop Trauma. 2019 Feb;33(2):e39-e45. doi: 10.1097/BOT.0000000000001348.

PMID:
30688837
33.

Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs.

Flerin NC, Bardhi A, Zheng JH, Korom M, Folkvord J, Kovacs C, Benko E, Truong R, Mota T, Connick E, Jones RB, Lynch RM, Goldstein H.

J Virol. 2019 Mar 5;93(6). pii: e02051-18. doi: 10.1128/JVI.02051-18. Print 2019 Mar 15.

34.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2019 Mar;78(3):399-405. doi: 10.1136/annrheumdis-2018-214245. Epub 2019 Jan 5.

PMID:
30612116
35.

Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS.

Bone Marrow Transplant. 2019 Aug;54(8):1245-1253. doi: 10.1038/s41409-018-0405-0. Epub 2018 Dec 10.

PMID:
30532055
36.

Publisher Correction: Evidence that CD32a does not mark the HIV-1 latent reservoir.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB.

Nature. 2018 Nov;563(7733):E33. doi: 10.1038/s41586-018-0611-3.

PMID:
30315222
37.

Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A.

JCI Insight. 2018 Oct 4;3(19). pii: 122673. doi: 10.1172/jci.insight.122673.

38.

Multicentred randomised controlled trial of an augmented exercise referral scheme using web-based behavioural support in individuals with metabolic, musculoskeletal and mental health conditions: protocol for the e-coachER trial.

Ingram W, Webb D, Taylor RS, Anokye N, Yardley L, Jolly K, Mutrie N, Campbell JL, Dean SG, Greaves C, Steele M, Lambert JD, McAdam C, Jane B, King J, Jones RB, Little P, Woolf A, Erwin J, Charles N, Terry RH, Taylor AH; Trial Steering Committee.

BMJ Open. 2018 Sep 21;8(9):e022382. doi: 10.1136/bmjopen-2018-022382.

39.

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J, Hamour S, Burns A, Griffith M, Galliford J, Levy JB, Cairns TD, Gopaluni S, Jones RB, Jayne D, Little MA, Pusey CD, Salama AD.

Rheumatology (Oxford). 2019 Feb 1;58(2):260-268. doi: 10.1093/rheumatology/key288. Erratum in: Rheumatology (Oxford). 2019 Feb 1;58(2):373.

40.

Evidence that CD32a does not mark the HIV-1 latent reservoir.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB.

Nature. 2018 Sep;561(7723):E20-E28. doi: 10.1038/s41586-018-0495-2. Epub 2018 Sep 19. No abstract available. Erratum in: Nature. 2018 Nov;563(7733):E33.

41.

Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.

Ren Y, Korom M, Truong R, Chan D, Huang SH, Kovacs CC, Benko E, Safrit JT, Lee J, Garbán H, Apps R, Goldstein H, Lynch RM, Jones RB.

J Virol. 2018 Nov 12;92(23). pii: e00895-18. doi: 10.1128/JVI.00895-18. Print 2018 Dec 1.

42.

Short Communication: Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy.

Bachtel ND, Beckerle GA, Mota TM, Rougvie MM, Raposo RAS, Jones RB, Nixon DF, Apps R.

AIDS Res Hum Retroviruses. 2019 Jan;35(1):108-111. doi: 10.1089/AID.2018.0162. Epub 2018 Oct 16.

43.

Phylogenetic approach to recover integration dates of latent HIV sequences within-host.

Jones BR, Kinloch NN, Horacsek J, Ganase B, Harris M, Harrigan PR, Jones RB, Brockman MA, Joy JB, Poon AFY, Brumme ZL.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967. doi: 10.1073/pnas.1802028115. Epub 2018 Sep 5.

44.

HLA-C downregulation by HIV-1 adapts to host HLA genotype.

Bachtel ND, Umviligihozo G, Pickering S, Mota TM, Liang H, Del Prete GQ, Chatterjee P, Lee GQ, Thomas R, Brockman MA, Neil S, Carrington M, Bwana B, Bangsberg DR, Martin JN, Kallas EG, Donini CS, Cerqueira NB, O'Doherty UT, Hahn BH, Jones RB, Brumme ZL, Nixon DF, Apps R.

PLoS Pathog. 2018 Sep 4;14(9):e1007257. doi: 10.1371/journal.ppat.1007257. eCollection 2018 Sep.

45.

Effectiveness of six core strategies based on trauma informed care in reducing seclusions and restraints at a child and adolescent psychiatric hospital.

Azeem M, Aujla A, Rammerth M, Binsfeld G, Jones RB.

J Child Adolesc Psychiatr Nurs. 2017 Nov;30(4):170-174. doi: 10.1111/jcap.12190.

PMID:
30129244
46.

Greater Microbial Translocation and Vulnerability to Metabolic Disease in Healthy Aged Female Monkeys.

Wilson QN, Wells M, Davis AT, Sherrill C, Tsilimigras MCB, Jones RB, Fodor AA, Kavanagh K.

Sci Rep. 2018 Jul 27;8(1):11373. doi: 10.1038/s41598-018-29473-9.

47.

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure.

Clutton GT, Jones RB.

Front Immunol. 2018 Jun 22;9:1452. doi: 10.3389/fimmu.2018.01452. eCollection 2018. Review.

48.

Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.

Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, Smith RM, Jayne DRW.

Ann Rheum Dis. 2018 Oct;77(10):1440-1447. doi: 10.1136/annrheumdis-2017-212861. Epub 2018 Jun 27.

49.

Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.

Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A.

AIDS Res Hum Retroviruses. 2018 Sep;34(9):769-777. doi: 10.1089/AID.2018.0098. Epub 2018 Aug 10.

50.

Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.

Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, Watson CJE, O'Sullivan AM, Chadwick JA, Foster KE, Jones RB, Devey LR, Richards A, Erwig LP, Savage CO, Smith KGC, Henderson RB, Clatworthy MR.

Lancet. 2018 Jun 30;391(10140):2619-2630. doi: 10.1016/S0140-6736(18)30984-X. Epub 2018 Jun 14.

PMID:
29910042

Supplemental Content

Loading ...
Support Center